Stephan Voss' principal research interest is in developing novel tools to more specifically image malignant disease. The goal of his work, using neuroblastoma both as a laboratory research and clinical model, is to develop neuroblastoma-specific imaging tools that permit pediatric radiologists to image the childhood malignancy with greater sensitivity and specificity. He is the chair of the Imaging section for the multi-center, NCI-sponsored Children's Oncology Group Phase I Consortium.
Reseach in the Voss laboratory is aimed at developing an animal model for neuroblastoma that can be readily imaged using either a small bore animal magnet, or small animal nuclear medicine cameras.
Voss and colleagues are developing and testing targeted contrast agents, using single chain antibodies derived from intact antibodies with reactivity against neuroblastoma. The single chain antibody (sFv) work involves a team of investigators directed at creating NB- specific, high sensitivity contrast agents by covalently conjugating small tumor targeting antibody fragments (sFv) to nuclear medicine agents, which include both conventional SPECT agents such as 99mTc and novel PET agents such as 64Cu.
In addition to these basic research pursuits, Voss' group is working pediatric oncologists to develop a more systematic assessment of the optimal imaging strategy for diagnosis and follow-up imaging in children with various cancers.
About Stephan Voss
Stephan Voss received his MD degree from the University of Wisconsin. He completed an internship at New England Deconess Hospital, a residency at Beth Israel Deaconess Medical Center and a fellowship at Boston Children's Hospital.